The core idea behind biomimetic nanomedicine is deceptively simple. Nanoparticles, whether synthetic or natural in origin, are coated with materials derived from living cells, such as membranes from platelets, macrophages, neutrophils, natural killer cells, erythrocytes, or even cancer cells themselves. Alternatively, they can be decorated with naturally derived biomolecules like monoclonal antibodies, viral capsids, and natural proteins, or with synthetic analogues such as targeting peptides and aptamers. This biological disguise confers several decisive advantages. The particles circulate in the bloodstream for longer periods, evade recognition by the reticuloendothelial system, accumulate preferentially in tumor tissue, and provoke far fewer unwanted immune reactions than conventional nanocarriers. In effect, the drug carrier stops looking like a foreign invader and starts looking like something the body already tolerates.

The review grounds this technological optimism in a detailed account of colon cancer biology. The disease typically unfolds over ten to twenty years through the well-characterized adenoma-carcinoma sequence. Loss of the APC tumor suppressor gene triggers uncontrolled proliferation and the formation of benign polyps. Subsequent activation of the KRAS oncogene drives growth into a large adenoma, while deletion of the DCC gene, involved in cell adhesion and apoptosis, permits abnormal cells to invade neighboring tissue. The final transformation comes with loss of p53, the guardian of DNA repair and programmed cell death, after which cells accumulate further mutations, breach the basement membrane, and metastasize to organs such as the liver and lungs. Understanding this stepwise molecular progression, the authors argue, is essential for designing nanocarriers that intervene at the right biological moment.

Among the most striking platforms described in the review are cell membrane-coated nanoparticles. By wrapping a synthetic drug-loaded core in the membrane of a red blood cell, platelet, or immune cell, researchers inherit the surface chemistry of that cell, including its complement-regulating proteins and adhesion molecules. Preclinical work highlighted in the review illustrates the potential vividly. In a mouse model of inflammation-driven colorectal cancer, biomimetic PLGA nanoparticles coated with red blood cell membranes and loaded with the enzyme shikimokinase produced stable body weights, reduced disease activity scores, longer colons, fewer tumor nodules, restored crypt architecture on histology, and enhanced apoptosis of tumor cells as measured by TUNEL staining. The membrane-coated formulations outperformed their uncoated counterparts across every endpoint, a result the authors present as evidence that biomimicry is not merely cosmetic but functionally therapeutic.

Exosome-based carriers represent a second major pillar. Exosomes are naturally occurring extracellular vesicles that cells use to communicate, and their innate ability to cross biological barriers makes them attractive delivery vehicles. Yet the review is candid about their limitations. Isolation methods such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture yield heterogeneous populations with inconsistent purity, undermining reproducibility. Cargo loading through passive incubation, electroporation, or chemical transfection still suffers from low encapsulation rates and rapid release. Once injected, exosomes face rapid clearance, aggregation, and degradation in circulation. Engineering strategies, including genetic modification of donor cells to display tumor-targeting peptides on the exosome surface, offer improved intrinsic targeting, while surface functionalization provides greater flexibility and scalability. The authors call for systematic studies of drug loading, release kinetics, and therapeutic efficacy to establish the standardized protocols that clinical translation will demand.

Inorganic and metal-based nanoparticles form a third, chemically diverse family. Gold nanoparticles, ranging from one to one thousand nanometers and available in spherical, rod, star, and cage morphologies, can convert near-infrared light into heat, making them potent agents for photothermal therapy. In one study cited in the review, photostable gold nanoparticles averaging roughly 180 nanometers were absorbed by colon cancer cells, as confirmed by increased cellular granularity, and produced a dramatic drop in cell viability after treatment. Silver nanoparticles take a different route, generating reactive oxygen species that induce oxidative stress, mitochondrial damage, membrane rupture, and apoptosis. Research on the SW480 colon cancer cell line showed that silver nanoparticles functionalized with glutamine and conjugated with thiosemicarbazide triggered apoptosis through notable caspase activation and downregulation of the HULC long non-coding RNA and the PPFIA4 oncogene. Silver nanoparticles can also enhance the tumor accumulation of conventional drugs like doxorubicin while reducing toxicity to healthy tissue, and their strong light-scattering properties make them useful as contrast agents in dark-field microscopy and surface-enhanced Raman scattering.

The review also catalogs the contributions of softer organic platforms. Dendrimers, tree-like branched macromolecules whose size and surface chemistry are controlled generation by generation, can be loaded with drugs in their interior cavities or conjugated to their periphery. Fourth-generation PAMAM dendrimers carrying capecitabine shrank tumors in mouse models with fewer effects on blood and liver than the free drug, while pegylated PAMAM dendrimers decorated with AS1411 anti-nucleolin aptamers showed heightened sensitivity against HT29 and C26 colorectal cancer cells and efficacy in tumor-bearing mice. A fifth-generation L-lysine dendrimer modified with polyoxazoline improved the therapeutic index of SN-38, the active metabolite of irinotecan, by controlling drug release and extending circulation time. Liposomes, the oldest clinical nanomedicine platform, continue to evolve: FDA-approved formulations such as Doxil and DaunoXome established the field in the 1990s, and temperature-sensitive liposomal doxorubicin, known as Thermodox, delivered twenty-five times more drug to cancer cells than standard intravenous delivery in preclinical testing for colorectal liver metastases.

Carbon nanotubes and quantum dots round out the arsenal. Carbon nanotubes, cylindrical rolls of hexagonally bonded carbon atoms a few nanometers in diameter, penetrate plasma membranes readily thanks to their needle-like shape and vast surface area. Combining single-walled carbon nanotubes with the TRAIL protein increased the death rate in colorectal cancer cell lines roughly tenfold, and carboxylic acid functionalization exploits the acidic lysosomal environment of cancer cells, around pH 5.5 versus 7.4 in healthy tissue, to trigger pH-dependent drug release. Quantum dots, semiconductor particles smaller than ten nanometers, offer exceptional fluorescence and photochemical stability for bioimaging, and carbon quantum dots are emerging as diagnostic and therapeutic tools in their own right. The review notes that colon cancers frequently overexpress placenta-specific protein 1, providing a molecular anchor for targeted nanoparticle binding.

The translational picture is genuinely encouraging but far from settled. The review catalogs a growing roster of clinical trials involving nanotechnology in colon and gastrointestinal cancers, including studies of cetuximab-loaded nanoparticles, liposomal irinotecan combined with FOLFIRI and bevacizumab, liposomal mitomycin-C with capecitabine, and nanoliposomal irinotecan paired with TAS-102. Yet the authors are clear that major bottlenecks remain: scalable manufacturing, batch-to-batch reproducibility, and demanding regulatory pathways under FDA and EMA frameworks. Their proposed solutions include cost-effective microfluidic production, automated bioreactors, comprehensive protocols for exosome isolation and nanoparticle characterization, and early harmonization with regulatory safety and quality standards. Looking forward, they envision theranostic platforms that merge diagnosis and treatment in a single particle, biomimetic carriers that ferry gene-editing tools alongside chemotherapy, nanomaterials engineered to reprogram the tumor microenvironment, and the encapsulation of plant-derived phytochemicals to overcome their poor solubility and low bioavailability. If interdisciplinary collaboration can close the gap between laboratory proof-of-concept and clinical practice, the authors conclude, biomimetic nanomaterials could move colon cancer therapy decisively closer to being safer, more effective, and personally tailored.

Subject of Research: Biomimetic nanomaterials for targeted drug delivery in colon cancer

Article Title: Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer

Article References: Dharme, K. K., Jain, P., Verma, G., & Uddin, A. (2026). Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer. Holistic Integrative Oncology, 5(1), Article 58. https://doi.org/10.1007/s44178-026-00279-4

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00279-4

Keywords: colon cancer, biomimetic nanoparticles, drug delivery, exosomes, cell membrane coating, gold nanoparticles, silver nanoparticles, dendrimers, liposomes, carbon nanotubes, quantum dots, nanomedicine

The core insight behind the study is that soft tissue breakdown around implants is not simply a matter of insufficient attachment. Instead, the researchers describe an early pathogenic-immunological amplification loop. Staphylococcus aureus, a bacterium with a particular affinity for titanium surfaces, is among the first colonizers of a fresh implant. Its accumulation, combined with surgical trauma and implant-induced oxidative stress, drives macrophages into a dysfunctional, pro-inflammatory state. Sustained inflammatory signaling then damages fibroblasts, impairs extracellular matrix remodeling, and blocks vascular maturation, all of which undermine the connective tissue barrier that should protect the implant. Disrupting this loop, the authors reasoned, requires a therapy that can target both the bacterium and the stressed immune cells at the same time.

Their solution, called MoSe2@SPMM, is a two-layer construction. At its heart sits a molybdenum diselenide nanoflower, a member of the nanozyme family of artificial enzyme mimics. MoSe2 carries intrinsic multi-enzyme catalytic activity that scavenges reactive oxygen species, mimicking catalase, glutathione peroxidase, and superoxide dismutase. It also converts near-infrared light into heat efficiently, and the material’s molybdenum and selenium components are individually associated with favorable biocompatibility. Wrapped around this reactive core is a cell membrane shell harvested from macrophages that had been deliberately pre-stimulated with S. aureus. The coating is applied through ultrasonication and extrusion, leaving a continuous membranous shell visible in transmission electron microscopy around a particle roughly 218 nanometers in hydrodynamic diameter before coating.

The choice of a bacteria-stimulated membrane is the study’s most elegant twist. Proteomic profiling of macrophages after S. aureus exposure revealed 534 upregulated and 235 downregulated proteins, with enrichment overwhelmingly concentrated in bacterial recognition, pattern-recognition-receptor signaling, and Toll-like receptor pathways. Follow-up transcriptional and protein analyses showed that TLR2, TLR6, and the scavenger receptor CD36 were selectively upregulated on the macrophage membrane, while virus-associated receptors stayed flat. When these membranes were transferred onto MoSe2, Western blots confirmed the nanoparticles retained elevated levels of all three recognition molecules. The result is a nanoparticle dressed in a molecular disguise that bacteria find irresistible to bind, and one that other macrophages recognize as kin.

Laboratory testing bore out the dual-targeting hypothesis. Compared with nanoparticles coated in unstimulated macrophage membranes, red blood cell membranes, or synthetic DOPC lipid shells, MoSe2@SPMM showed dramatically stronger binding to S. aureus in both scanning electron and confocal microscopy, while showing no such preference for E. coli, a sign of genuine selectivity. When near-infrared light at 808 nanometers was applied, the bound particles converted light to heat at the bacterial surface, producing what the authors call targeted contact-enhanced photothermal killing. Bacterial membranes roughened, perforated, and collapsed, and colony assays showed the treatment dramatically outperformed controls. Against biofilms, which are far more resistant and clinically relevant, the particles not only suppressed formation but also disrupted established structures, killing bacteria throughout the biofilm depth rather than only at the surface.

The second axis of action operates inside immune cells. Because the coating carries homotypic recognition features, MoSe2@SPMM is preferentially internalized by macrophages themselves, while fibroblasts and endothelial cells take up far less of it. Once inside oxidative-stress-injured macrophages, the nanoparticle’s enzymatic core mops up excess reactive oxygen species. In vitro, the particles removed roughly 75 to 88 percent of hydrogen peroxide within an hour at moderate concentrations, generated dissolved oxygen, and quenched both superoxide and hydroxyl radicals in electron spin resonance assays, with activity persisting over repeated catalytic cycles. In cells, treatment lowered intracellular ROS, restored mitochondrial membrane potential, suppressed the pro-inflammatory marker iNOS, revived the repair-associated marker Arg-1, and shifted the secretome away from TNF-alpha and IL-6 toward IL-10 and TGF-beta.

Those cellular changes rippled outward to the tissue-building cells that determine whether a soft tissue seal can form. Conditioned medium from MoSe2@SPMM-treated macrophages restored the proliferation, migration, and tube-forming capacity of vascular endothelial cells under oxidative stress, accompanied by recovered expression of VEGF-A and FGF2, two master regulators of angiogenesis. Fibroblasts responded similarly, regaining migration and adhesion while rebuilding focal adhesion protein vinculin, fibronectin 1, and both collagen I and collagen III, the structural foundation of the peri-implant connective tissue. Biosafety testing was reassuring: the particles were compatible with cells up to 200 micrograms per milliliter, caused negligible hemolysis, and produced no histological, hematological, or liver and kidney abnormalities in treated animals.

The decisive test came in a rat maxillary implantation model in which S. aureus was inoculated at the peri-implant site to simulate early post-surgical stress. Under localized near-infrared irradiation, MoSe2@SPMM reduced the peri-implant bacterial burden by 91.4 percent, substantially outperforming both control coatings. Immunofluorescence at day 7 showed a marked shift in macrophage identity, with fewer iNOS-positive pro-inflammatory cells and more Arg-1-positive repair-associated cells. By day 28, the treated implants displayed denser alpha-SMA-positive vascular maturation, a 1.7-fold increase in peri-implant connective tissue width, 67.1 percent greater collagen deposition with better fiber organization, 61.4 percent higher integrin expression at the tissue-implant interface, and a 2.3-fold increase in angiogenesis. The animals developed a continuous epithelial barrier and reduced inflammatory infiltration, hallmarks of robust soft tissue integration.

What distinguishes this platform from conventional implant surface engineering is its mode of delivery and breadth of function. Surface-bound coatings fight a losing battle against the oral environment, gradually losing bioactivity and offering only single-function protection. MoSe2@SPMM, by contrast, is designed for local administration at the implant-soft tissue interface, potentially injected around the transgingival neck during early healing or under high-risk inflammatory conditions, then activated with intraoral near-infrared probes. The authors also suggest the design principle could extend beyond dentistry to orthopedic and percutaneous devices, wherever bacterial colonization, oxidative stress, and dysregulated inflammation jointly sabotage tissue repair.

Challenges remain before clinical translation. The rat model used controlled S. aureus inoculation rather than the polymicrobial biofilms characteristic of established human peri-implantitis, so real-world efficacy will need confirmation in more complex settings. Optimal treatment windows, irradiation parameters, repeat dosing schedules, and scalable membrane-coating manufacturing all require refinement. Yet the conceptual achievement is clear: by teaching a nanoparticle to hunt one specific bacterium and simultaneously nurse the immune cells back to health, the researchers have demonstrated that targeted antibacterial action and redox-mediated immune regulation can be fused into a single therapy, offering a genuinely new strategy for protecting the fragile seal on which every dental implant ultimately depends.

Subject of Research: Dual-targeted biomimetic MoSe2 nanozymes coated with S. aureus-stimulated macrophage membranes for enhancing peri-implant soft tissue integration

Article Title: Dual‐Targeted Biomimetic MoSe2 Nanozymes for Enhancing Peri‐Implant Soft Tissue Integration

Article References: Zhou, M., Tian, M., Yu, J., Kang, J., Chen, M., Yuan, Y., Liu, L., & Wei, H. (2026). Dual‐Targeted Biomimetic MoSe 2 Nanozymes for Enhancing Peri‐Implant Soft Tissue Integration. Advanced Science, Article e77771. https://doi.org/10.1002/advs.77771

Image Credits: AI Generated

DOI: 10.1002/advs.77771

Keywords: MoSe2 nanozymes, peri-implantitis, soft tissue integration, biomimetic nanoparticles, cell membrane coating, Staphylococcus aureus, photothermal therapy, macrophage reprogramming, reactive oxygen species, dental implants, immunomodulation, oxidative stress

Graphitic carbon nitride, often abbreviated as g-C3N4, is a two-dimensional polymeric material composed of carbon and nitrogen arranged in heptazine or triazine ring structures. It has attracted intense interest in photocatalysis because it absorbs visible light, is chemically robust, and contains no heavy metals. In biomedical contexts, these properties matter enormously: nanoparticles that persist in the body must not leach toxic ions, and materials activated by light in the visible or near-infrared range can be triggered from outside the body with spatial precision. What has limited clinical translation, however, is that bare carbon nitride particles are recognized and cleared by the immune system, aggregate in physiological salt concentrations, and lack any built-in affinity for the diseased tissues they are meant to treat.

The new study addresses these shortcomings by wrapping the nanoparticles in natural cell membranes, a strategy known as biomimetic coating. By cloaking graphitic carbon nitride nanoparticles in membranes derived from cells, the researchers effectively gave the particles a biological disguise. The membrane coating preserves the surface markers and proteins that cells use to communicate with their surroundings, allowing the nanoparticles to evade rapid immune clearance, navigate the complex protein milieu of blood, and preferentially accumulate at target sites such as tumors or inflamed tissue. This approach borrows directly from the way pathogens and circulating tumor cells disguise themselves to survive in the bloodstream, turning a survival trick of biology into an engineering tool.

The phrase multiscale photomodulation in the study’s title captures the platform’s defining feature. At the molecular scale, photoexcitation of graphitic carbon nitride generates electron-hole pairs that can drive the production of reactive oxygen species, the chemical basis of photodynamic therapy. At the cellular scale, these reactive species can damage cancer cell membranes, mitochondria, and DNA, triggering cell death pathways. At the tissue and organ scales, the particles’ light absorption and conversion properties can be harnessed for imaging, for localized heating through photothermal effects, and for modulating biological processes such as inflammation or neuronal activity. A single nanomaterial, the authors argue, can therefore serve as an optical actuator operating simultaneously at the molecular, cellular, and organismal levels.

Photodynamic therapy, one of the central applications, relies on photosensitizers that, upon light activation, transfer energy to ground-state oxygen to produce singlet oxygen and other cytotoxic reactive species. Conventional photosensitizers frequently suffer from poor water solubility, insufficient tissue penetration of the activating light, and off-target toxicity when illuminated light reaches healthy tissue. Graphitic carbon nitride nanoparticles offer an alternative photosensitizer with strong photocatalytic activity under visible light, high photostability that resists photobleaching, and a metal-free composition that simplifies regulatory and toxicity considerations. The biomimetic coating adds a layer of targeting that improves the therapeutic window by concentrating the photosensitizer where it is needed.

The therapeutic breadth described in the work extends beyond tumor ablation. Because light can be applied, removed, or tuned in real time, the platform functions as a programmable intervention: clinicians could in principle control the dose of reactive oxygen species or heat delivered to a lesion by adjusting illumination intensity, wavelength, and duration. The researchers describe applications in antimicrobial treatment, where photoinduced reactive species can kill drug-resistant bacteria without contributing to antibiotic resistance, and in immune modulation, where controlled photochemistry at the surface of membrane-coated particles can influence inflammatory signaling. Such versatility is rare in a single nanoplatform and reflects the underlying tunability of the semiconductor’s electronic structure.

A key technical achievement highlighted in the study is the stability of the membrane-nanoparticle hybrid in physiological conditions. Bare nanoscale semiconductors tend to aggregate in serum because proteins and salts screen electrostatic repulsion between particles. The biomimetic coating, by presenting a hydrated, biologically familiar surface, suppresses aggregation and prolongs circulation time. The coating also changes biodistribution: instead of being trapped rapidly by the liver and spleen, the disguised particles can circulate longer and exploit biological homing mechanisms, such as the affinity of tumor-cell membranes for their parent tumor tissue, to reach disease sites more efficiently. This homologous targeting principle has emerged in recent years as one of the most promising strategies in nanomedicine.

The work also speaks to a broader shift in how researchers think about the interface between synthetic materials and living systems. Rather than attempting to out-engineer biology with ever more exotic synthetic chemistries, the biomimetic approach integrates biological components directly into the material’s architecture. In this case, the rigid, optically active semiconductor core supplies the physical function, light harvesting and energy conversion, while the soft biological shell supplies the systemic function, immune evasion and targeting. The division of labor between core and shell illustrates a design philosophy that could extend to other two-dimensional materials, including transition-metal dichalcogenides and black phosphorus, which face similar barriers to biomedical use.

Safety remains a central question for any nanomaterial intended for clinical use, and the metal-free nature of graphitic carbon nitride is a meaningful advantage. Materials such as quantum dots containing cadmium or lead raise persistent concerns about long-term accumulation and ion release, whereas carbon nitride degrades into comparatively benign carbon- and nitrogen-containing species. The authors emphasize that biodegradability and clearance must still be rigorously characterized in advanced animal models and, eventually, in clinical trials, but the composition of the material removes an entire class of toxicity concerns at the outset.

The study’s authors position the platform as a foundation rather than a finished product. Future work, they suggest, could pair the particles with complementary light sources such as implantable LEDs or upconversion systems that shift near-infrared light into wavelengths the material absorbs more efficiently, extending treatment depth beyond the millimeter scale of conventional photodynamic therapy. Combining the photomodulation platform with immunotherapy, gene delivery, or responsive drug release could yield closed-loop systems in which light both diagnoses and treats. As biomimetic nanomaterials continue to mature, graphitic carbon nitride nanoparticles that speak the language of biology while harnessing the power of light may prove to be one of the more durable bridges between materials science and medicine.

Subject of Research: Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and light-activated therapeutic intervention

Article Title: Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention

Article References: Müller, C. A., Klompmaker, K. K., Zhang, Y., Zhang, J., Kalatanova, A., Li, P., Meng, L., Madsen, J. G., Jakobsen, T. S., Jørgensen, A. C., Askou, A. L., Luo, Y., Lin, L., Vogt Bleshøy, S., Bolis, G., Huang, G., Li, W., Davidsen, R. S., Bek, T., … Chen, M. (2026). Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01773-w

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01773-w

Keywords: graphitic carbon nitride, nanoparticles, biomimetic coating, photodynamic therapy, photomodulation, nanomedicine, reactive oxygen species, drug delivery, photothermal therapy, cell membrane coating, biodegradable nanomaterials, light-activated therapy